STUDY OBJECTIVE: To evaluate the pharmacokinetics of gentamicin in neonates with hypoxic ischemic encephalopathy (HIE) receiving hypothermia and to identify an empiric gentamicin dosing strategy in this population that optimizes achievement of target peak and trough concentrations. DESIGN: Population pharmacokinetic study using retrospective medical record data. SETTING: Tertiary neonatal intensive care unit. PATIENTS: A total of 29 full-term neonates diagnosed with HIE treated with hypothermia who received gentamicin and underwent therapeutic drug monitoring MEASUREMENT AND MAIN RESULTS: Patient demographics and gentamicin concentration data were retrospectively collected over a 2-year period. A population-based pharmacokinetic model was developed using nonlinear mixed-effects modeling (NONMEM). Using the developed model, Monte Carlo simulations were performed to evaluate the probability of achieving target peak (> 6 mg/L) and trough (< 2 mg/L) gentamicin concentrations for various potential dosing regimens. A one-compartment model best described the available gentamicin concentration data. Birthweight and serum creatinine significantly influenced gentamicin clearance. For the typical study neonate (birthweight 3.3 kg, serum creatinine 0.9 mg/dl), clearance was 0.034 L/hour/kg and volume was 0.52 L/kg. At a 24-hour dosing interval, Monte Carlo simulations predicted target gentamicin peak and trough concentrations could not be reliably achieved at any dose. At a 36-hour dosing interval, a dose of 4-5 mg/kg is predicted to achieve target gentamicin peak and trough concentrations in more than 90% of neonates. CONCLUSIONS: Gentamicin clearance is decreased in neonates with HIE treated with hypothermia compared with previous reports in nonasphyxiated normothermic full-term neonates. A prolonged 36-hour dosing interval will be needed to achieve target gentamicin trough concentrations in this population. Further prospective evaluation of this dosing recommendation is needed.
STUDY OBJECTIVE: To evaluate the pharmacokinetics of gentamicin in neonates with hypoxic ischemicencephalopathy (HIE) receiving hypothermia and to identify an empiric gentamicin dosing strategy in this population that optimizes achievement of target peak and trough concentrations. DESIGN: Population pharmacokinetic study using retrospective medical record data. SETTING: Tertiary neonatal intensive care unit. PATIENTS: A total of 29 full-term neonates diagnosed with HIE treated with hypothermia who received gentamicin and underwent therapeutic drug monitoring MEASUREMENT AND MAIN RESULTS:Patient demographics and gentamicin concentration data were retrospectively collected over a 2-year period. A population-based pharmacokinetic model was developed using nonlinear mixed-effects modeling (NONMEM). Using the developed model, Monte Carlo simulations were performed to evaluate the probability of achieving target peak (> 6 mg/L) and trough (< 2 mg/L) gentamicin concentrations for various potential dosing regimens. A one-compartment model best described the available gentamicin concentration data. Birthweight and serum creatinine significantly influenced gentamicin clearance. For the typical study neonate (birthweight 3.3 kg, serum creatinine 0.9 mg/dl), clearance was 0.034 L/hour/kg and volume was 0.52 L/kg. At a 24-hour dosing interval, Monte Carlo simulations predicted target gentamicin peak and trough concentrations could not be reliably achieved at any dose. At a 36-hour dosing interval, a dose of 4-5 mg/kg is predicted to achieve target gentamicin peak and trough concentrations in more than 90% of neonates. CONCLUSIONS:Gentamicin clearance is decreased in neonates with HIE treated with hypothermia compared with previous reports in nonasphyxiated normothermic full-term neonates. A prolonged 36-hour dosing interval will be needed to achieve target gentamicin trough concentrations in this population. Further prospective evaluation of this dosing recommendation is needed.
Authors: Jeffrey M Perlman; Jonathan Wyllie; John Kattwinkel; Dianne L Atkins; Leon Chameides; Jay P Goldsmith; Ruth Guinsburg; Mary Fran Hazinski; Colin Morley; Sam Richmond; Wendy M Simon; Nalini Singhal; Edgardo Szyld; Masanori Tamura; Sithembiso Velaphi Journal: Circulation Date: 2010-10-19 Impact factor: 29.690
Authors: Sonia L Bonifacio; Hannah C Glass; Juliana Vanderpluym; Ashish T Agrawal; Duan Xu; A James Barkovich; Donna M Ferriero Journal: J Pediatr Date: 2010-10-20 Impact factor: 4.406
Authors: Elisabet I Nielsen; Marie Sandström; Per Hartvig Honoré; Uwe Ewald; Lena E Friberg Journal: Clin Pharmacokinet Date: 2009 Impact factor: 6.447
Authors: Denis V Azzopardi; Brenda Strohm; A David Edwards; Leigh Dyet; Henry L Halliday; Edmund Juszczak; Olga Kapellou; Malcolm Levene; Neil Marlow; Emma Porter; Marianne Thoresen; Andrew Whitelaw; Peter Brocklehurst Journal: N Engl J Med Date: 2009-10-01 Impact factor: 91.245
Authors: Nicole R Zane; Michael D Reedy; Marc R Gastonguay; Adam S Himebauch; Evan Z Ramsey; Alexis A Topjian; Athena F Zuppa Journal: Pediatr Crit Care Med Date: 2017-07 Impact factor: 3.624
Authors: Tamara van Donge; Marc Pfister; Julia Bielicki; Chantal Csajka; Frederique Rodieux; John van den Anker; Aline Fuchs Journal: Antimicrob Agents Chemother Date: 2018-03-27 Impact factor: 5.191
Authors: Kacey B Anderson; Samuel M Poloyac; Patrick M Kochanek; Philip E Empey Journal: Ther Hypothermia Temp Manag Date: 2016-09-13 Impact factor: 1.286
Authors: Adam Frymoyer; Sonia L Bonifacio; David R Drover; Felice Su; Courtney J Wustoff; Krisa P Van Meurs Journal: J Clin Pharmacol Date: 2016-06-26 Impact factor: 3.126
Authors: Yuma A Bijleveld; Timo R de Haan; Hanneke J H van der Lee; Floris Groenendaal; Peter H Dijk; Arno van Heijst; Rogier C J de Jonge; Koen P Dijkman; Henrica L M van Straaten; Monique Rijken; Inge A Zonnenberg; Filip Cools; Alexandra Zecic; Debbie H G M Nuytemans; Anton H van Kaam; Ron A A Mathot Journal: Br J Clin Pharmacol Date: 2016-03-10 Impact factor: 4.335
Authors: Christopher McPherson; Adam Frymoyer; Cynthia M Ortinau; Steven P Miller; Floris Groenendaal Journal: Semin Fetal Neonatal Med Date: 2021-06-23 Impact factor: 3.926
Authors: Mario R Sampson; Adam Frymoyer; Benjamin Rattray; C Michael Cotten; P Brian Smith; Edmund Capparelli; Sonia L Bonifacio; Michael Cohen-Wolkowiez Journal: Ther Drug Monit Date: 2014-10 Impact factor: 3.118